title: CSF and plasma amyloid-β temporal profiles and relationships with neurological status and mortality after severe traumatic brain injury.
abstract: The role of amyloid-β (Aβ) neuropathology and its significant changes in biofluids after traumatic brain injury (TBI) is still debated. We used ultrasensitive digital ELISA approach to assess amyloid-β1-42 (Aβ42) concentrations and time-course in cerebrospinal fluid (CSF) and in plasma of patients with severe TBI and investigated their relationship to injury characteristics, neurological status and clinical outcome. We found decreased CSF Aβ42 levels in TBI patients acutely after injury with lower levels in patients who died 6 months post-injury than in survivors. Conversely, plasma Aβ42 levels were significantly increased in TBI with lower levels in patients who survived. A trend analysis showed that both CSF and plasma Aβ42 levels strongly correlated with mortality. A positive correlation between changes in CSF Aβ42 concentrations and neurological status as assessed by Glasgow Coma Scale (GCS) was identified. Our results suggest that determination of Aβ42 may be valuable to obtain prognostic information in patients with severe TBI as well as in monitoring the response of the brain to injury.
authors.affiliation: Department of Neurosciences, University of Messina, Messina, Italy.
authors.forename: Stefania
authors.initials: S
authors.lastname: Mondello
authors.affiliation: Department of Neurosurgery, University of Pecs, and MTA-PTE Clinical Neuroscience MR Research Group, Pecs, Hungary.
authors.forename: Andras
authors.initials: A
authors.lastname: Buki
authors.affiliation: Department of Neurosurgery University of Szeged, Szeged, Hungary.
authors.forename: Pal
authors.initials: P
authors.lastname: Barzo
authors.affiliation: Quanterix Corporation, 113 Hartwell Ave., Lexington, MA, USA.
authors.forename: Jeff
authors.initials: J
authors.lastname: Randall
authors.affiliation: Quanterix Corporation, 113 Hartwell Ave., Lexington, MA, USA.
authors.forename: Gail
authors.initials: G
authors.lastname: Provuncher
authors.affiliation: Quanterix Corporation, 113 Hartwell Ave., Lexington, MA, USA.
authors.forename: David
authors.initials: D
authors.lastname: Hanlon
authors.affiliation: Quanterix Corporation, 113 Hartwell Ave., Lexington, MA, USA.
authors.forename: David
authors.initials: D
authors.lastname: Wilson
authors.affiliation: Dept of Biochemistry and Molecular Biology, American University of Beirut, Beirut, Lebanon.
authors.forename: Firas
authors.initials: F
authors.lastname: Kobeissy
authors.affiliation: Quanterix Corporation, 113 Hartwell Ave., Lexington, MA, USA.
authors.forename: Andreas
authors.initials: A
authors.lastname: Jeromin
mesh_terms: D000328:Adult; D000368:Aged; D016229:Amyloid beta-Peptides / Q000097:blood* / Q000134:cerebrospinal fluid*; D001921:Brain / Q000473:pathology; D001930:Brain Injuries / Q000097:blood* / Q000134:cerebrospinal fluid* / Q000473:pathology; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D015600:Glasgow Coma Scale; D006801:Humans; D008297:Male; D008875:Middle Aged; D010446:Peptide Fragments / Q000097:blood* / Q000134:cerebrospinal fluid*; D011379:Prognosis
chemical_list: D016229:Amyloid beta-Peptides; D010446:Peptide Fragments; C075222:amyloid beta-protein (1-42)